Navigation Links
Brand Drug 'Copay Coupons' Undermine Generics, Raise Health Costs by $2.3 Billion in New York
Date:11/17/2011

WASHINGTON, Nov. 17, 2011 /PRNewswire-USNewswire/ -- The proliferation of brand drug "copay coupon" promotions, which lure insured consumers from generics to more expensive brands, will increase costs by $2.3 billion in New York over the next decade for employers, unions, and state employee plans, according to new research from Visante and released by the Pharmaceutical Care Management Association (PCMA). The use of these promotions by state and local government workers alone will cost New York taxpayers an extra $379 million over ten years.

Click here to read the study

Unlike groceries and other goods that are purchased directly by consumers, 2/3 of prescription drug costs are paid by the employers, unions, and government agencies (i.e., taxpayers) that provide coverage, not consumers themselves. Though banned as illegal kickbacks in federal health programs, copay coupons are unregulated in the commercial market (except Massachusetts).

To minimize premiums and reduce costs, those who offer prescription drug coverage assign higher copays to expensive brands and lower copays to more affordable drugs that treat the same condition. In response, drug companies now offer coupons that cover the higher copays but not the cost of the actual drug. By covering a $50 copay to sell a $150 brand, drug companies extract an extra $100 from the employer, union, or government agency that offers coverage. This helps explain why copay coupons target only those with insurance (i.e., those who pay copays), not the poor or uninsured.

"Brand copay coupons lure patients from generics to expensive brands and stick employers, unions, and government employee health programs with the extra costs," said PCMA President and CEO Mark Merritt. "In New York, taxpayers will pay an extra $379 million just to cover the use of brand copay coupons by government workers in state and municipal employee health programs."

Drug companies profit from coupon promotions in several ways:

  • Copay coupons induce consumers to choose higher-cost brands (despite higher copays) over lower-cost competitors (despite lower copays). When consumers redeem copay coupons, the drug companies process them through a "shadow claims system" that prevents employers and other plan sponsors from knowing when enrollees have used them.
  • Drug companies often require consumers to submit confidential, personal information in order to redeem copay coupons. Manufacturers have long sought (but found difficult to obtain) such sensitive patient data, which enables them to identify and directly target individual patients with "brand loyalty" marketing programs.

Coupons can also increase consumer costs in several ways:

  • To help cover the $4 billion spent annually on copay coupons nationally, manufacturers can simply raise prices. Manufacturers reportedly earn a 4:1 to 6:1 return on investment (ROI) on copay coupon programs.
  • Copay coupons create "brand loyalty" to the most expensive products in each therapeutic class of drugs, even among newly diagnosed patients.

PCMA represents the nation's pharmacy benefit managers (PBMs), which improve affordability and quality of care through the use of electronic prescribing (e-prescribing), generic alternatives, mail-service pharmacies, and other innovative tools for 210-plus million Americans.

Follow PCMA on Twitter


'/>"/>
SOURCE Pharmaceutical Care Management Association
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Brand Drug Copay Coupons Undermine Generics, Raise Health Costs by $681 Million in Missouri
2. Brand Drug Copay Coupons Undermine Generics, Raise Health Costs by $1.4 Billion in Illinois
3. Brand Drug Copay Coupons Undermine Generics, Raise Health Costs by $1 Billion in New Jersey
4. Brand Drug Copay Coupons Undermine Generics, Raise Health Costs by $1.1 Billion in Michigan
5. Brand Drug Copay Coupons Undermine Generics, Raise Health Costs by $308 Million in Arkansas
6. Brand Drug Copay Coupons Undermine Generics, Raise Health Costs by $447 Million in Connecticut
7. Brand Drug Copay Coupons Undermine Generics, Raise Health Costs by $2.1 Billion in Florida
8. Report: Brand Drug Copay Coupons Raise Health Costs for Employers, Unions, and State Governments by $32 Billion
9. UBM Live to Roll Out Pharma Contract Services & Outsourcing Brand in the US in 2012
10. Popular Sleep Supplement Brand Settles Patent Infringement Suit Against Store Brand Manufacturer
11. Prasco Named Exclusive U.S. Distributor for Selected Aspen Branded Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... DUBLIN , Feb 24, 2017 Research ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... provides drug pricing data and benchmarks in the global Urinary Incontinence ... What are the key drugs marketed for Urinary Incontinence ...
(Date:2/23/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device company ... the urology market, will release financial results for the ... before the market open on Thursday, March 9, 2017. ... call and webcast to discuss its financial results the ... a.m. Eastern Time (10:00 a.m. Central Time). Darin ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica ... in thought leadership , media relations, social media, content marketing and SEO, ... be powered through Act-On, an intuitive marketing automation platform. , Rosica will now ...
(Date:2/23/2017)... ... 23, 2017 , ... On February 22, 2017 the U.S. ... to withdraw previous guidance issued by the Obama Administration requiring schools to treat ... 2016 by the Obama Administration came in response to a growing number of ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The American Cleft ... ACPA’s 74th Annual Meeting. KLS is a longtime supporter of the event. , ... exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information Services ... Institute for Health and Care Excellence (NICE) framework. The agreement allows purchasers ... (NHS) to search, order and purchase medical and healthcare-related content through GOBI ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
Breaking Medicine News(10 mins):